1138804--1/7/2008--UNICA_CORP

related topics
{acquisition, growth, future}
{product, market, service}
{system, service, information}
{regulation, change, law}
{property, intellectual, protect}
{customer, product, revenue}
{regulation, government, change}
{stock, price, operating}
{control, financial, internal}
{personnel, key, retain}
{stock, price, share}
{cost, contract, operation}
{operation, international, foreign}
The delay or cancellation of one or more large transactions may adversely affect our quarterly or annual revenue. If we fail to develop or acquire new software products or enhance existing products, we will not be able to achieve our anticipated level of growth. A substantial majority of our perpetual license revenue is derived from our Affinium Campaign software, and a decline in sales of licenses of this software could materially adversely affect our operating results. If we fail to protect our proprietary rights and intellectual property adequately, our business and prospects may be harmed. Competition from EMM, enterprise application and infrastructure software, as well as from internally developed solutions, could adversely affect our ability to sell our software products and related services and could result in pressure to price our products in a manner that reduces our margins. If we do not maintain and strengthen our strategic alliance relationships, our ability to generate revenue and manage expenses could be adversely affected. If we fail to retain our chief executive officer or other key personnel or if we fail to attract additional qualified personnel, we will not be able to achieve our anticipated level of growth and our operating results could be adversely affected. Our international operations expose us to additional business risks, and failure to manage these risks may adversely affect our business and operating results. New accounting standards or interpretations of existing accounting standards could adversely affect our operating results. Our business continues to grow rapidly in size and complexity which may affect our ability to effectively comply with new and existing regulations affecting our business. If the material weakness in our internal control over financial reporting that we have identified is not remedied effectively, it could result in a material misstatement in our financial statements not being prevented or detected and could adversely affect investor confidence in the accuracy and completeness of our financial statements, and could have an adverse effect on the trading price of our common stock. Our inability to sustain our historical maintenance renewal rates and pricing would adversely affect our operating results. If we fail to manage our expanding operations effectively, we may not be able to achieve our anticipated level of growth and our operating results could be adversely affected. Defects or errors in our software products could harm our reputation, impair our ability to sell our products and result in significant costs to us. We intend to increase the amount of revenue that we derive from subscription arrangements, which may cause our quarterly revenue and other operating results to fail to meet expectations. Privacy and security concerns, including evolving government regulation in the area of consumer data privacy, could adversely affect our business and operating results. Intellectual property litigation and infringement claims may cause us to incur significant expenses or prevent us from selling our software products. We may enter into acquisitions that may be difficult to integrate, disrupt our business, dilute stockholder value or divert management attention. We will continue to incur significant costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives. Risks Relating to Ownership of Our Common Stock The price of our common stock may be volatile.

Full 10-K form ▸

related documents
1058083--2/21/2006--IMS_HEALTH_INC
1121439--3/17/2008--EMAGEON_INC
1058083--2/25/2008--IMS_HEALTH_INC
1019737--2/28/2008--NAVIGANT_CONSULTING_INC
1121439--3/16/2007--EMAGEON_INC
912544--3/17/2008--HOLLYWOOD_MEDIA_CORP
1200022--3/16/2007--INTEGRATED_ALARM_SERVICES_GROUP_INC
1056696--3/15/2006--MANHATTAN_ASSOCIATES_INC
1138804--12/15/2008--UNICA_CORP
1056696--3/14/2007--MANHATTAN_ASSOCIATES_INC
1111634--3/16/2009--XO_HOLDINGS_INC
1121439--3/31/2006--EMAGEON_INC
1045014--1/22/2008--GAMETECH_INTERNATIONAL_INC
1141107--3/1/2007--ARRIS_GROUP_INC
845818--3/2/2006--RADIANT_SYSTEMS_INC
897893--5/12/2008--PEERLESS_SYSTEMS_CORP
351903--9/9/2010--EPOCH_HOLDING_CORP
103145--2/28/2008--VEECO_INSTRUMENTS_INC
1287258--3/15/2006--PLANETOUT_INC
1021162--5/22/2009--TRIUMPH_GROUP_INC_/
927355--6/19/2006--TESSCO_TECHNOLOGIES_INC
352079--3/14/2006--TVI_CORP
1058083--2/26/2007--IMS_HEALTH_INC
920527--5/26/2010--PSS_WORLD_MEDICAL_INC
1057758--2/28/2008--TIME_WARNER_TELECOM_INC
1021162--5/28/2008--TRIUMPH_GROUP_INC_/
1020859--9/27/2010--UNITED_NATURAL_FOODS_INC
1350156--9/15/2008--SUN_WORLD_PARTNERS_INC
1124941--12/1/2009--BEACON_ROOFING_SUPPLY_INC
820081--5/26/2006--CAMBREX_CORP